Clinical Trial

A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 18, 2022 (before its estimated June 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
An open-label, single-arm, multicenter, prospective clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma
Trial Details
NCT Number NCT05506410
Lead Sponsor Zhengzhou University
Conditions Newly Diagnosed Mantle Cell Lymphoma
Enrollment 100 participants
Start Date 2022-08-12
Primary Completion 2024-06-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2022-08-18